Literature DB >> 22915459

Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.

Kay Seden1, Saye H Khoo, David Back, Pauline Byakika-Kibwika, Mohammed Lamorde, Mairin Ryan, Concepta Merry.   

Abstract

Scale-up of HIV treatment services may have contributed to an increase in functional health facilities available in resource-limited settings and an increase in patient use of facilities and retention in care. As more patients are reached with medicines, monitoring patient safety is increasingly important. Limited data from resource-limited settings suggest that medication error and antiretroviral drug-drug interactions may pose a significant risk to patient safety. Commonly cited causes of medication error in the developed world include the speed and complexity of the medication use cycle combined with inadequate systems and processes. In resource-limited settings, specific factors may contribute, such as inadequate human resources and high disease burden. Management of drug-drug interactions may be complicated by limited access to alternative medicines or laboratory monitoring. Improving patient safety by addressing the issue of antiretroviral drug-drug interactions has the potential not just to improve healthcare for individuals, but also to strengthen health systems and improve vital communication among healthcare providers and with regulatory agencies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22915459     DOI: 10.1093/jac/dks346

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Effect of drug interactions involving antiretroviral drugs on viral load in HIV population.

Authors:  Carles Iniesta-Navalón; Juan José Franco-Miguel; Juan José Gascón-Cánovas; Lorena Rentero-Redondo
Journal:  Eur J Hosp Pharm       Date:  2015-06-18

2.  Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine.

Authors:  Stephen I Walimbwa; Mohammed Lamorde; Catriona Waitt; Julian Kaboggoza; Laura Else; Pauline Byakika-Kibwika; Alieu Amara; Joshua Gini; Markus Winterberg; Justin Chiong; Joel Tarning; Saye H Khoo
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study.

Authors:  C Schlaeppi; F Vanobberghen; G Sikalengo; T R Glass; R C Ndege; G Foe; A Kuemmerle; D H Paris; M Battegay; C Marzolini; M Weisser
Journal:  HIV Med       Date:  2019-09-18       Impact factor: 3.180

4.  Potential drug-drug interactions of antiretrovirals and antimicrobials detected by three databases.

Authors:  Pornpun Vivithanaporn; Teetat Kongratanapasert; Bovornpat Suriyapakorn; Pichayut Songkunlertchai; Patpicha Mongkonariyawong; Patanachai K Limpikirati; Phisit Khemawoot
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

5.  An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).

Authors:  Stephen I Walimbwa; Julian P Kaboggoza; Catriona Waitt; Pauline Byakika-Kibwika; Antonio D'Avolio; Mohammed Lamorde
Journal:  Trials       Date:  2021-11-23       Impact factor: 2.279

6.  Use of non-HIV medication among people living with HIV and receiving antiretroviral treatment in Côte d'Ivoire, West Africa: A cross-sectional study.

Authors:  Mariam Mama Djima; Didier Koumavi Ekouevi; Jean-Pierre Gregoire; Boris Tchounga; Patrick Ahuatchi Coffie; Viet-Thi Tran; Franck Y Touré; Jocelyne Moisan
Journal:  PLoS One       Date:  2019-09-16       Impact factor: 3.240

7.  Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda.

Authors:  K Seden; C Merry; R Hewson; M Siccardi; M Lamorde; P Byakika-Kibwika; E Laker; R Parkes-Ratanshi; D J Back; S H Khoo
Journal:  J Antimicrob Chemother       Date:  2015-08-18       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.